checkAd
    Black Diamond Therapeutics Aktie
    5,8900
     
    USD
    +15,26 %
    +0,7800 USD
    Letzter Kurs 27.04.24 Nasdaq
    5,8800
     
    USD
    600 STK
    Geldkurs 26.04.24
    5,8900
     
    USD
    100 STK
    Briefkurs 26.04.24
    ISIN: US09203E1055 · WKN: A2PYWB · SYM: BDTX · USA

    Neueste Nachrichten

    Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Announces Changes to Board of Directors
    11.04.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
    08.04.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    03.04.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    12.03.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
    05.03.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
    28.02.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
    04.01.24 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    07.11.23 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    06.11.23 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
    14.10.23 · globenewswire · Black Diamond Therapeutics
    Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    04.10.23 · globenewswire · Black Diamond Therapeutics